2018年7月11日紐約——輝瑞公司今天宣布將公司重組為三塊業務：基于科學的創新藥品業務（生物類似藥和專注于抗感染及無菌注射劑產品的醫院業務部也將包括在內）；專注于過專利期品牌藥及仿制藥、并在輝瑞內部擁有相當自主性的成熟藥品業務；以及健康藥物業務。這些變化將于2019財年開始生效。

“這一新架構反映了這些業務的自然演進。這是基于我們已上市產品和即將上市的在研產品的持續走強，以及樂瑞卡在美國市場2018年12月（或之后）專利到期后，預計2020年以后由于專利到期所造成的影響將大幅降低。我們預計2020年之后將有更快和更持續的業務收入增長組合。在此過渡期間，我們認為這一新架構將使各塊業務更好地定位以達到其增長潛力。”輝瑞公司董事長兼首席執行官晏瑞德（Ian Read）表示。

創新藥品業務將包括輝瑞目前所有輝瑞創新醫療業務部門，以及一個新的經營輝瑞全球無菌注射劑和抗感染藥品組合的醫院藥品業務部。這將使我們更加專注和以用戶為中心。同時輝瑞還會將生物類似藥、腫瘤、炎癥及免疫業務并入創新藥品業務。這些業務部門在其各自治療領域都具備很強的醫學、商務和患者體驗方面的能力，將為這些藥品提供一個強大的商業化平臺。

人口老齡化帶來的對新的創新藥物日益增長的需求和生物技術快速發展帶來的突破性治療方案是創新藥品業務迅猛增長的基礎。輝瑞相信，基于強勁的增長中的上市產品組合、2020年開始預期的新一波新品上市，輝瑞的創新藥品業務正蓄勢待發。

成熟藥品業務將包括輝瑞大部分專利到期固體口服藥物品牌，如樂瑞卡、立普妥、絡活喜、萬艾可等，以及某些仿制藥。這塊業務將在世界各區域運營。為了讓該業務行動迅速和靈活，它將有其自己獨有和專職的生產、市場、法規職能，在一些例外情況下還包括支持部門，這將提高其自主性并在輝瑞內部像一個真正獨立的部門運作。

在樂瑞卡于2018年12月（或之后）在美國的專利到期所預期造成的影響過后，輝瑞預計成熟藥品業務收入有潛力產生可持續的適度增長。新興市場，尤其是亞洲的城市化和中產階級的興起提供了額外的準入機會以及對成熟的品牌藥和仿制藥的強勁需求。作為在亞洲，尤其是在中國的制藥公司，我們相信輝瑞具有在這一重要和快速發展的市場上的優勢。

“為全球患者提供關鍵藥物仍然是我們在輝瑞工作的指南。這一新的架構設計能使我們在多元化的市場里更加專注于多元化的患者。”輝瑞首席運營官艾伯樂(Albert Bourla)表示。“此外，這一架構將使成熟藥品業務能化其特有的增長機會，同時提供在未來抓住提升其價值的各種機會的靈活性。”

健康藥物業務將包括所有輝瑞非處方藥產品，將繼續相對自主地運營，并將有其專門的生產和法規職能。

健康藥物業務基礎增長強勁，同時又與其他兩塊處方藥業務有所不同。消費者主義的趨勢以及不斷增長的對持續健康的專注使消費者尋求易于獲得的健康和養生解決方案。擁有一個強大的橫跨健康和養生領域的全球品牌組合，公司相信該業務能很好地保持其增長。輝瑞將繼續評估該業務的戰略選擇并預期在2018年內做出決定。

這些組織架構的變化預計不會影響目前的資源分配重點和2018財政年度的財務指南。基于2017年的實際結果，創新藥品業務（包括健康藥物）預計將占輝瑞總收入的四分之三，成熟藥品業務將占大約四分之一。輝瑞將在2019一季度財報發布時提供反映這一新架構的財務報告。

當這些調整生效時，黃瑋明（Angela Hwang）和楊宇翰(John Young) 將分別領導輝瑞創新藥品業務的不同部分，并向艾伯樂匯報。

楊宇翰，集團總裁，將負責內科藥品、腫瘤（包括生物類似藥）和罕見病業務部門。此外，他還將負責在所有新興市場的創新藥品業務。

黃瑋明，集團總裁，將負責炎癥及免疫（包括生物類似藥）、疫苗和醫院藥品業務部。此外，她還將領導輝瑞健康藥物業務。

成熟藥品業務將由Michael Goettler領導，他將成為輝瑞執行管理團隊成員并向艾伯樂匯報。Goettler先生有著23年從業經驗，他在2007年隨著對惠氏的收購而加入輝瑞。之后擔任過一系列職責日益重要的高級管理職務，涉及普藥、特藥等多個治療領域。Goettler先生有著豐富的業務管理經驗并在多個市場和區域生活和工作過，包括亞太和歐洲。他負責輝瑞罕見病業務并推動公司涉足基因治療領域。他現任輝瑞炎癥及免疫全球總裁。Goettler先生畢業于德國Koblenz企業管理學院并擁有德克薩斯大學MBA學位。

以上架構變化取決于和各地員工組織或工會的協商，以及其他法律要求。

DISCLOSURE NOTICE: The information contained in this release is as of July 11, 2018. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about, among other things, Pfizer, its expected growth profile, its plans to organize the company into a new structure consisting of three businesses and the anticipated performance of those businesses, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, risks related to the ability to realize the anticipated benefits of the organization of the company into the new structure, including the possibility that the expected benefits from the new structure will not be realized or will not be realized within the expected time period; the risk that the businesses will not be organized into the new structure successfully; the potential for disruption from the organization of the company into the new structure and diversion of management’s attention from other aspects of our business as a result of the organization into the new structure; significant transaction costs; other business effects, including the effects of industry, market, economic, political or regulatory conditions; future exchange and interest rates; changes in tax and other laws, regulations, rates and policies; future business combinations or disposals; the uncertainties inherent in research and development, including the ability to meet anticipated trial commencement and completion dates and regulatory submission dates, as well as the possibility of unfavorable clinical trial results, including unfavorable new clinical data and additional analyses of existing clinical data; whether and when any drug applications may be filed in any jurisdictions for any pipeline assets or new indications for marketed products; whether and when regulatory authorities may approve any such applications, which will depend on its assessment of the benefit-risk profile suggested by the totality of the efficacy and safety information submitted and, if approved, whether they will be commercially successful; decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of the company’s pipeline assets or marketed products; competitive developments; risks and uncertainties related to our evaluation of strategic alternatives for our Consumer Healthcare business, including, among other things, the ability to realize the anticipated benefits of any strategic alternatives we may pursue for our Consumer Healthcare business, the potential for disruption to our business and diversion of management’s attention from other aspects of our business, the possibility that such strategic alternatives will not be completed on terms that are advantageous to Pfizer, the possibility that we may be unable to realize a higher value for our Consumer Healthcare business through strategic alternatives, and unknown liabilities. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.